NASDAQ:KURA - Kura Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.33
  • Forecasted Upside: -3.48 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$35.57
▼ -0.78 (-2.15%)
1 month | 3 months | 12 months
Get New Kura Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KURA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KURA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$34.33
▼ -3.48% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $34.33, with a high forecast of $43.00 and a low forecast of $24.00. The average price target represents a -3.48% upside from the last price of $35.57.
Buy
The current consensus among 10 contributing investment analysts is to buy stock in Kura Oncology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2020Piper SandlerDowngradeOverweight ➝ Neutral$25.00 ➝ $34.00Medium
i
10/26/2020JMP SecuritiesBoost Price Target$22.00 ➝ $33.00High
i
10/12/2020HC WainwrightBoost Price TargetBuy$22.00 ➝ $40.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
10/8/2020CSFBBoost Price TargetOutperform$27.00 ➝ $43.00Low
i
10/8/2020Credit Suisse GroupBoost Price TargetOutperform$27.00 ➝ $43.00Medium
i
9/30/2020BarclaysBoost Price TargetPositive ➝ Overweight$32.00 ➝ $37.00Low
i
Rating by Peter Lawson at Barclays PLC
8/31/2020BarclaysBoost Price TargetOverweight$24.00 ➝ $32.00Medium
i
Rating by Peter Lawson at Barclays PLC
8/16/2020Brookline Capital ManagementReiterated RatingBuyLow
i
Rating by L. Cann at Brookline Capital Management
7/7/2020Credit Suisse GroupInitiated CoverageOutperform$27.00High
i
5/31/2020OppenheimerInitiated CoverageBuy$23.00 ➝ $27.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/29/2020HC WainwrightReiterated RatingBuy$22.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/19/2020Deutsche Bank AktiengesellschaftLower Price TargetBuy$28.00 ➝ $24.00Medium
i
5/6/2020WedbushLower Price TargetOutperform$30.00 ➝ $28.00Medium
i
5/5/2020OppenheimerLower Price TargetOutperform$27.00 ➝ $23.00Medium
i
5/5/2020HC WainwrightLower Price TargetBuy$29.00 ➝ $22.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/4/2020BarclaysInitiated CoverageOverweight$24.00Low
i
Rating by Peter Lawson at Barclays PLC
2/26/2020Piper SandlerLower Price Target$32.00 ➝ $30.00High
i
12/16/2019HC WainwrightReiterated RatingBuy$29.00Low
i
12/6/2019CowenReiterated RatingBuyHigh
i
11/6/2019CowenReiterated RatingBuyMedium
i
9/5/2019JMP SecuritiesReiterated RatingMarket Outperform$22.00High
i
9/4/2019WedbushReiterated RatingOutperform ➝ PositiveLow
i
Rating by Robert Driscoll at Wedbush
8/2/2019HC WainwrightReiterated RatingBuy$29.00Low
i
Rating by Joseph Pantginis at HC Wainwright
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$28.00High
i
6/17/2019CowenReiterated RatingBuyMedium
i
6/17/2019WedbushSet Price TargetOutperform ➝ Positive$23.00 ➝ $30.00High
i
6/15/2019SVB LeerinkSet Price TargetBuy$27.00Low
i
Rating by Jonathan Chang at SVB Leerink LLC
5/24/2019CitigroupBoost Price TargetBuy$18.00 ➝ $25.00High
i
5/8/2019HC WainwrightSet Price TargetBuy$31.00Low
i
Rating by Joseph Pantginis at HC Wainwright
3/19/2019OppenheimerReiterated RatingBuyMedium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/3/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
12/3/2018HC WainwrightReiterated RatingBuy$31.00Low
i
Rating by Joseph Pantginis at HC Wainwright
11/28/2018OppenheimerSet Price TargetBuy$32.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/9/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$25.00Low
i
11/1/2018HC WainwrightSet Price TargetBuy$31.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
10/22/2018CowenReiterated RatingBuyHigh
i
10/22/2018HC WainwrightReiterated RatingPositive ➝ Buy$31.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/7/2018HC WainwrightSet Price TargetBuy$31.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/1/2018HC WainwrightInitiated CoverageBuy$31.00High
i
Rating by J. Pantginis at HC Wainwright
7/9/2018OppenheimerBoost Price TargetOutperform$27.00 ➝ $35.00Medium
i
2/16/2018CitigroupSet Price TargetBuy$28.00High
i
12/26/2017WedbushInitiated CoverageBuy$19.00Medium
i
Rating by Robert Driscoll at Wedbush
12/20/2017WedbushInitiated CoverageOutperform$19.00High
i
Rating by R. Driscoll at Wedbush
12/11/2017OppenheimerSet Price TargetBuy$18.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/16/2017OppenheimerSet Price TargetBuy$18.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/9/2017CitigroupBoost Price TargetBuy$15.00 ➝ $19.00N/A
i
Rating by Joel Beatty at Citigroup Inc.
9/7/2017CowenInitiated CoverageOutperformMedium
i
8/10/2017SVB LeerinkReiterated RatingOutperform$16.00 ➝ $18.00High
i
8/8/2017CitigroupSet Price TargetBuy$13.00High
i
Rating by Joel Beatty at Citigroup Inc.
7/4/2017OppenheimerReiterated RatingBuy$16.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
6/28/2017OppenheimerReiterated RatingOutperform$16.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
6/14/2017OppenheimerSet Price TargetBuy$16.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
4/21/2017OppenheimerReiterated RatingOutperform$16.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
4/6/2017OppenheimerSet Price TargetBuy$16.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
3/17/2017OppenheimerReiterated RatingOutperform$18.00 ➝ $16.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
3/6/2017OppenheimerSet Price TargetBuy$18.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
2/9/2017OppenheimerReiterated RatingOutperform$16.00 ➝ $18.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
1/17/2017OppenheimerSet Price TargetBuy$16.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/7/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by J. Chang at SVB Leerink LLC
10/13/2016SVB LeerinkReiterated RatingOutperform$15.00N/A
i
8/14/2016OppenheimerReiterated RatingOutperform$16.00N/A
i
6/21/2016OppenheimerReiterated RatingOutperform$16.00N/A
i
Rating by Wendy Lam at Oppenheimer Holdings Inc.
3/21/2016CitigroupLower Price TargetBuy$19.00 ➝ $12.00N/A
i
Rating by Joel Beatty at Citigroup Inc.
2/11/2016OppenheimerReiterated RatingOutperformN/A
i
Rating by Wendy Lam at Oppenheimer Holdings Inc.
1/22/2016JMP SecuritiesInitiated CoverageOutperform$24.00N/A
i
12/30/2015OppenheimerInitiated CoverageOutperform$16.00 ➝ $16.00N/A
i
12/16/2015CitigroupInitiated CoverageBuyN/A
i
(Data available from 11/26/2015 forward)
Kura Oncology logo
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $35.57
$35.41
$36.81

50 Day Range

MA: $34.50
$29.00
$40.07

52 Week Range

Now: $35.57
$6.35
$40.62

Volume

387,682 shs

Average Volume

581,475 shs

Market Capitalization

$2.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31